|
gptkbp:instance_of
|
gptkb:physicist
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Russian_Ice_Hockey_Federation
gptkb:HC_Almaty
|
|
gptkbp:associated_with
|
gptkb:hemangioblastomas
gptkb:healthcare_organization
gptkb:pheochromocytomas
|
|
gptkbp:caused_by
|
mutation in the VHL gene
|
|
gptkbp:clinical_trial
|
ongoing
|
|
gptkbp:complications
|
gptkb:healthcare_organization
kidney failure
vision loss
|
|
gptkbp:current_use
|
gptkb:Von_Hippel-Lindau_syndrome
|
|
gptkbp:descendant
|
autosomal dominant
|
|
gptkbp:discovered_by
|
gptkb:Arvid_Carlsson
|
|
gptkbp:first_described_by
|
gptkb:1964
|
|
gptkbp:function
|
tumor suppression
|
|
gptkbp:genetic_diversity
|
recommended
|
|
gptkbp:habitat
|
3p25.3
|
|
gptkbp:healthcare
|
gptkb:VHL_Alliance
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
VHL
|
|
gptkbp:is_popular_in
|
1 in 36,000
|
|
gptkbp:provides_information_on
|
ESMO guidelines
NCCN guidelines
|
|
gptkbp:public_awareness
|
gptkb:VHL_Awareness_Day
gptkb:Educational_Institution
community outreach
|
|
gptkbp:receives_funding_from
|
non-profit organizations
government grants
private donations
|
|
gptkbp:research_focus
|
tumor suppressor genes
cancer genetics
|
|
gptkbp:risk_factor
|
family history
genetic predisposition
|
|
gptkbp:screenings
|
blood pressure monitoring
annual MRI
ultrasound of kidneys
|
|
gptkbp:social_responsibility
|
variable
genetic testing
depends on stage of disease
depends on tumor type
|
|
gptkbp:symptoms
|
blood tests
vision problems
high blood pressure
headaches
regular check-ups
imaging tests
|
|
gptkbp:treatment
|
gptkb:hospital
gptkb:vaccine
gptkb:drug
surveillance
radiation therapy
targeted therapy
improved with early detection
depends on tumor management
varies by treatment type
|